Caplin Point Laboratories Limited has announced its financial results for the half year ended September 30, 2026. The company reported a 19.1% increase in total revenue to ₹1,307.0 crore and a 16.2% rise in Profit After Tax (PAT) to ₹361.4 crore compared to the previous year. EBITDA also saw a substantial increase of 19.8%. The results reflect the company’s consistent growth across various segments and markets, including a strong performance in emerging markets and the US.
Caplin Point Announces Strong H1 FY27 Financial Performance
Caplin Point Laboratories Limited today announced its financial results for the half-year and second quarter ended September 30, 2026. The company has demonstrated robust growth, with total revenue reaching ₹1,307.0 crore for the half year, marking an increase of 19.1% year-on-year. Profit After Tax (PAT) for the same period grew by 16.2% to ₹361.4 crore.
Key Financial Highlights (H1 FY27 vs H1 FY26)
- Revenue from Operations: Increased by 18.8% to ₹1,240.2 crore.
- Total Revenue: Grew by 19.1% to ₹1,307.0 crore.
- Gross Profit: Increased by 18.4% to ₹756.3 crore.
- EBITDA: Saw a significant increase of 19.8% to ₹503.5 crore.
- Profit Before Tax (PBT): Rose by 18.8% to ₹458.05 crore.
- Profit After Tax (PAT): Increased by 16.2% to ₹361.4 crore.
Second Quarter Performance (Q2 FY27 vs Q2 FY26)
For the second quarter ended September 30, 2026, Caplin Point reported a 17.9% increase in Revenue from Operations to ₹629.8 crore and a 13.8% rise in Profit After Tax (PAT) to ₹182.4 crore.
Business Highlights
The company highlighted several key achievements and strategic initiatives:
- Emerging Markets: Steady growth in Latin America, with successful tender wins in Central America ($5.3 million) and Chile ($5 million). Commencement of oncology sales in Mexico and progress in developing a robust R&D pipeline.
- US & Regulated Markets: Caplin Steriles USA (CSU) has surpassed its full FY26 sales in the first six months of its second year, indicating strong traction in the US market. CSU has filed over 120 products in non-US markets, with plans for 60+ more filings in the next 18 months.
- Capacity Expansion: The company is investing in new capacities and capabilities, including oncology, APIs, the COL-II facility, and pre-filled syringes.
- Financial Position: Free cash reserves stand at ₹1,534 crore, with total liquid assets at ₹2,967 crore, positioning the company to fund its expansion plans.
The Board of Directors approved these Un-audited standalone and consolidated financial results at their meeting held on November 12, 2026.
Source: BSE
